Lemsip Cold & Flu Hot Lemon 500mg Powder for Oral Solution * General Sale: Non-prescription
Company:
Reckitt Benckiser Ireland LimitedStatus:
UpdatedLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 04 August 2022
File name
62eb9b33d92cd.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 04 August 2022
File name
62eb9a595eddc.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Updated on 04 August 2022
File name
62eb9a32e3b1b.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 27 October 2021
File name
PIL Lemsip C&F Headcold 10's TR2290239C- CRN009859 &CRN008LKW_1635334844.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
Updated on 27 October 2021
File name
SPC Lemsip CF Headcold_1635334749.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Updated on 15 January 2020
File name
Lemsip Cold & Flu Hot Lemon 500mg Powder for Oral Solution_1579098656.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 18 January 2017
File name
PIL_14946_891.pdf
Reasons for updating
- New PIL for new product
Updated on 18 January 2017
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
Updated on 29 November 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Updated on 29 November 2016
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.9 - Overdose
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.4:
Deletion of warning "if symptoms persist, the physician should be consulted"
Addition of warning "if symptoms persist for more than seven days, please consult a healthcare professional"
Section 4.6:
Deletion of "For short term use in all trimesters of pregnancy. There is epidemiological evidence of safety in human pregnancy. Patients should follow the advice of their doctor regarding the use of paracetamol during pregnancy".
Addition of "A large amount of data on pregnancy women indicate neither malformative, nor feto/neonatal toxicity. paracetamol can be used during pregnancy If clinically needed however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency".
Section 4.9:
Addition of new data in relation to risk factors, symptoms and overdose management.
Deletion of warning "if symptoms persist, the physician should be consulted"
Addition of warning "if symptoms persist for more than seven days, please consult a healthcare professional"
Section 4.6:
Deletion of "For short term use in all trimesters of pregnancy. There is epidemiological evidence of safety in human pregnancy. Patients should follow the advice of their doctor regarding the use of paracetamol during pregnancy".
Addition of "A large amount of data on pregnancy women indicate neither malformative, nor feto/neonatal toxicity. paracetamol can be used during pregnancy If clinically needed however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency".
Section 4.9:
Addition of new data in relation to risk factors, symptoms and overdose management.
Updated on 10 August 2015
Reasons for updating
- Change to further information section
Updated on 30 January 2015
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 2 - added Lactose to list of excipients
Section 4.4 - added warning regarding presence of Lactose
Section 6.1 - added to list of excipients: Lactose, polysorbate 80, and Silica
Section 10 - Changed date of revision of text to January 2014
Section 4.4 - added warning regarding presence of Lactose
Section 6.1 - added to list of excipients: Lactose, polysorbate 80, and Silica
Section 10 - Changed date of revision of text to January 2014
Updated on 30 March 2011
Reasons for updating
- New PIL for medicines.ie
Updated on 29 October 2009
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 9 - Date of renewal of authorisation
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 1: Strengh and form included in name
Section 9: change date of ast renewal
Section 9: change date of ast renewal
Updated on 15 May 2007
Reasons for updating
- Change to marketing authorisation holder address
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
SECTION 7. Change of address of marketing authorisation holder to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Updated on 29 August 2006
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 1: Trade Name - Should be Lemsip Cold & Flu Hot Lemon
Section 2: Qualitative and Quantitative Composition - Remove Ascorbic acid and Sodium citrate as actives
Section 4.4: Special Warnings and special precautions for use - Amount of carbohydrate in point 3 should be changed from 4.15g to 3g
Section 6.1 - List of excipients - Needs changing completely to : Sucrose, citric acid, Lemon flavour no.1, saccharin sodium, aspartame, sodium citrate, ascorbic acid and curcumin WD
Section 6.4 - Special precautions for storage - need to change 30°C to 25°C
Section 6.5 - Nature and contents of container - the words Surlyn laminate need changing to heat seal laminate
Section 10 - Date of (partial) Revision of the Text - should be April 2006
Updated on 19 May 2005
Reasons for updating
- Improved electronic presentation
Legal category:Supply through general sale
Updated on 10 August 2004
Reasons for updating
- Improved electronic presentation
Legal category:Supply through general sale
Updated on 16 June 2003
Reasons for updating
- New SPC for medicines.ie
Legal category:Supply through general sale